Roth Capital Upgrades Keryx Biopharmaceuticals (KERX) to Buy
Tweet
Share
E-mail
Get Alerts KERX Hot Sheet
Price: $3.36 --0%
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
Roth Capital upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Buy, price target raised from $4 to $7.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $1.45 yesterday.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $1.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
- Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'
- Jefferies Upgrades Sempra Energy (SRE) to Buy, 'Darkest Before Dawn in Texas and California'
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
